Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Momenta Phama (MNTA) Tops Q1 EPS by 14c, Revenues Beat
May 7, 2020 7:55 AM EDTMomenta Phama (NASDAQ: MNTA) reported Q1 EPS of ($0.34), $0.14 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $8.89 million versus the consensus estimate of $4.33 million.
Despite the turbulence imposed by the COVID-19 pandemic, Momenta has remained focused on advancing our development... More
